Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Zeina Haddad

Ophthalmology Southern Pines, NC Medical Doctor

NPI 1821251802 CMS profile 128461

2170 Midland Rd, Southern Pines, NC 28387

Open in the dashboard

General payments

$4,951

179 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zeina Haddad of Southern Pines, NC is reported in the CMS Open Payments database as having received $4,951 across 179 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $781 28
2024 General $960 29
2023 General $1,078 31
2022 General $975 29
2021 General $452 20
2020 General $430 28
2019 General $275 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zeina Haddad
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Zeina Haddad were reported at $781. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Zeina Haddad Ophthalmology median Middle half National median
2019 $275 $258 $104–$655 $163
2020 $430 $126 $45–$321 $114
2021 $452 $205 $76–$534 $132
2022 $975 $266 $100–$678 $149
2023 $1,078 $308 $117–$745 $160
2024 $960 $340 $127–$846 $164
2025 $781 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech USA, Inc. $1,729 46 payments
  2. Regeneron Healthcare Solutions, Inc. $634 9 payments
  3. Alcon Vision LLC $432 17 payments
  4. TissueTech, Inc. $370 35 payments
  5. Apellis Pharmaceuticals, Inc. $365 6 payments
  6. AbbVie, Inc. $284 15 payments
  7. Bausch & Lomb, a division of Bausch Health US, LLC $181 11 payments
  8. Biogen, Inc. $137 3 payments
  9. Alimera Sciences, Inc. $130 8 payments
  10. Novartis Pharmaceuticals Corporation $87 5 payments
  11. Other $603 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,951 179 payments
Products named General payments · program years 2019–2025
  1. VABYSMO $1,298 34 payments
  2. Lucentis Ophthalmology $545 14 payments
  3. EYLEA HD $323 4 payments
  4. EYLEA $311 5 payments
  5. Lucentis Ophthalmology $282 3 payments
  6. Syfovre $223 4 payments
  7. PROKERA $222 18 payments
  8. AMNIOGRAFT $222 18 payments
  9. Clareon $208 7 payments
  10. OZURDEX $190 10 payments
  11. Other $1,972 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

533

Median for Ophthalmology: 891

Drug cost

$22,212

Median for Ophthalmology: $68,233

Branded share of claims

20.8%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 176 $7,988
Lumigan Bimatoprost Brand 18 $5,124
Brimonidine Tartrate Generic 23 $2,531
Simbrinza Brinzolamide/Brimonidine Tart Brand 11 $2,269
Ketorolac Tromethamine Generic 73 $1,481
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 82 $1,325
Ofloxacin Generic 74 $872
Latanoprost Generic 61 $489
Timolol Maleate Generic 15 $133

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$3,138,554

Of which drugs: $2,719,239

Medicare patients

805

Average age 77

Services billed

69,987

473 women, 332 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 45%
Chronic kidney disease 35%
Ischemic heart disease 34%
Heart failure 23%
Depression 22%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, faricimab-svoa, 0.1 mg J2777 Office 227 60,480 $1,648,098
Injection, aflibercept, 1 mg J0178 Office 102 1,202 $780,760
Injection, ranibizumab, 0.1 mg J2778 Office 50 940 $125,178
Injection, aflibercept hd, 1 mg J0177 Office 11 328 $86,252
Injection, dexamethasone, intravitreal implant, 0.1 mg J7312 Office 24 378 $59,526
Injection, bevacizumab, 10 mg J9035 Office 48 195 $10,759

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VABYSMO
  • Genentech USA, Inc. $281
$281 — 60,480
Syfovre
  • Apellis Pharmaceuticals, Inc. $184
$184 — —
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $125
$125 — 328
OZURDEX
  • AbbVie, Inc. $61
$61 — 378
Lucentis
  • Genentech USA, Inc. $42
$42 — 940

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

179 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record